Testosterone is lower in men with non-alcoholic fatty liver disease and alcohol-related cirrhosis and is associated with adverse clinical outcomes

References

• Grossmann M, Hoermann R, Gani L, et al. Low testosterone levels as an independent predictor of mortality in men with chronic liver disease. Clin Endocrinol. 2012;77(2):323–328.
   PubMed Web of Science ®Google Scholar
• Gordon GG, Olivo J, Rafil F, et al. Conversion of androgens to estrogens in cirrhosis of the liver. J Clin Endocrinol Metab. 1975;40(6):1018–1026.
   PubMed Web of Science ®Google Scholar
• Vaishnav B, Tambile R, Minna K, et al. Study of gonadal hormones in males with liver cirrhosis and its correlation with child-turcotte-pugh and model for end-stage liver disease scores. Cureus. 2023;15(1):e34035.
   PubMed Web of Science ®Google Scholar
• Sinclair M, Grossmann M, Gow PJ, et al. Testosterone in men with advanced liver disease: abnormalities and implications. J Gastroenterol Hepatol. 2015;30(2):244–251.
   PubMed Web of Science ®Google Scholar
• Handelsman DJ, Strasser S, McDonald JA, et al. Hypothalamic‐pituitary‐testicular function in end‐stage non‐alcoholic liver disease before and after liver transplantation. Clin Endocrinol. 1995;43(3):331–337.
   PubMed Web of Science ®Google Scholar
• Foresta C, Schipilliti M, Ciarleglio FA, et al. Male hypogonadism in cirrhosis and after liver transplantation. J Endocrinol Invest. 2008;31(5):470–478.
   PubMed Web of Science ®Google Scholar
• Deng N, Mallepally N, Peng FB, et al. Serum testosterone levels and testosterone supplementation in cirrhosis: a systematic review. Liver Int. 2021;41(10):2358–2370.
   PubMed Web of Science ®Google Scholar
• Sarkar M, Lai JC, Sawinski D, et al. Sex hormone levels by presence and severity of cirrhosis in women with chronic hepatitis C virus infection. J Viral Hepat. 2019;26(2):258–262.
   PubMed Web of Science ®Google Scholar
• Sarkar MA, Suzuki A, Abdelmalek MF, et al. Testosterone is associated with nonalcoholic steatohepatitis and fibrosis in premenopausal women with NAFLD. Clin Gastroenterol H. 2021;19(6):1267–1274.e1.
   PubMed Web of Science ®Google Scholar
• Dittadi R, Matteucci M, Meneghetti E, et al. Reassessment of the access testosterone chemiluminescence assay and comparison with LC‐MS method. J Clin Lab Anal. 2018;32(3):e22286.
   PubMed Web of Science ®Google Scholar
• Kaymakoĝlu S, Ökten A, Çakaloĝlu Y, et al. Hypogonadism is not related to the etiology of liver cirrhosis. J Gastroenterol. 1995;30(6):745–750.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay SK, Moulick A, Saha M, et al. A study on endocrine dysfunction in adult males with liver cirrhosis. J Indian Med Assoc. 2009;107(12):868–869. 866,
   Google Scholar
• Wang YJ, Wu JC, Lee SD, et al. Gonadal dysfunction and changes in sex hormones in postnecrotic cirrhotic men: a matched study with alcoholic cirrhotic men. Hepato-gastroenterol. 1991;38(6):531–534.
   PubMedGoogle Scholar
• Duca Y, Aversa A, Condorelli RA, et al. Substance abuse and male hypogonadism. JCM. 2019;8(5):732.
   Google Scholar
• Jaruvongvanich V, Sanguankeo A, Riangwiwat T, et al. Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Hepatol. 2017;16(3):382–394.
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metabolism. 1999;84(10):3666–3672.
   PubMed Web of Science ®Google Scholar
• Sinclair M, Grossmann M, Hoermann R, et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial. J Hepatol. 2016;65(5):906–913.
   PubMed Web of Science ®Google Scholar
• Sinclair M, Grossmann M, Angus PW, et al. Low testosterone as a better predictor of mortality than sarcopenia in men with advanced liver disease. J Gastroenterol Hepatol. 2016;31(3):661–667.
   PubMed Web of Science ®Google Scholar
• Paternostro R, Heinisch BB, Reiberger T, et al. Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. Hepatol Res. 2019;49(2):201–211.
   PubMed Web of Science ®Google Scholar
• Sarkola T, Eriksson CJP. Testosterone increases in men after a low dose of alcohol. Alcoholism Clin Exp Res. 2003;27(4):682–685.
   PubMed Web of Science ®Google Scholar
• Emanuele MA, Emanuele NV. Alcohol’s effects on male reproduction. Alcohol Heal Res World. 1998;22(3):195–201.
   PubMedGoogle Scholar
• Grossmann M, Wierman ME, Angus P, et al. Reproductive endocrinology of nonalcoholic fatty liver disease. Endocr Rev. 2019;40(2):417–446.
   PubMed Web of Science ®Google Scholar
• Nguyen HV, Mollison LC, Taylor TW, et al. Chronic hepatitis C infection and sex hormone levels: effect of disease severity and recombinant interferon‐α therapy. Intern Med J. 2006;36(6):362–366.
   PubMed Web of Science ®Google Scholar
• Chaudhury CS, Mee T, Chairez C, et al. Testosterone in men with chronic hepatitis C infection and after hepatitis C viral clearance. Clin Infect Dis. 2019;69(4):ciy965.
   Web of Science ®Google Scholar
• Herbst KL, Bhasin S. Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care. 2004;7(3):271–277.
   PubMed Web of Science ®Google Scholar
• Montano–Loza AJ, Meza–Junco J, Prado CMM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10(2):166–173.e1.
   PubMed Web of Science ®Google Scholar
• Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019;1(4):312–328.
   PubMedGoogle Scholar
• Younossi ZM, Otgonsuren M, Venkatesan C, et al. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism. 2013;62(3):352–360.
   PubMed Web of Science ®Google Scholar
• Bertot LC, Adams LA. The natural course of non-alcoholic fatty liver disease. IJMS. 2016;17(5):774.
   Google Scholar
• Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9(1):32–45.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Alwani M, Talib R, et al. Long-term testosterone therapy improves liver parameters and steatosis in hypogonadal men: a prospective controlled registry study. Aging Male. 2020;23(5):1553–1563.
   PubMed Web of Science ®Google Scholar
• Albhaisi S, Kim K, Baker J, et al. LPCN 1144 resolves NAFLD in hypogonadal males. Hepatol Commun. 2020;4(10):1430–1440.
   PubMed Web of Science ®Google Scholar
• Maseroli E, Comeglio P, Corno C, et al. Testosterone treatment is associated with reduced adipose tissue dysfunction and nonalcoholic fatty liver disease in obese hypogonadal men. J Endocrinol Invest. 2020;44(4):1–24.
   PubMed Web of Science ®Google Scholar
• Nikolaenko L, Jia Y, Wang C, et al. Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats. Endocrinology. 2014;155(2):417–428.
   PubMed Web of Science ®Google Scholar
• Cai Z, Jiang X, Pan Y, et al. Transcriptomic analysis of hepatic responses to testosterone deficiency in miniature pigs fed a high-cholesterol diet. BMC Genomics. 2015;16(1):59.
   PubMedGoogle Scholar
• Hoyos CM, Yee BJ, Phillips CL, et al. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol. 2012;167(4):531–541.
   PubMed Web of Science ®Google Scholar
• Apostolov R, Gianatti E, Wong D, et al. Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations. World J Hepatol. 2022;14(4):754–765.
   PubMed Web of Science ®Google Scholar
• Adams LA, Roberts SK, Strasser SI, et al. NAFLD disease burden–Australia, 2019–2030. J Gastroen Hepatol. 2020;35(9):1628–1635.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the framingham heart study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96(8):2430–2439.
   PubMed Web of Science ®Google Scholar